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Abstract: For the first time introduced on the Japanese market, bioactive fish 
hydrolysates are now available all over the world as food supplements, functional 
food ingredients or nutricosmeceuticals. They are generally produced from low 
value fish waste, an almost inexhaustible source of raw material, and are sold as 
high value products, making them economically interesting from a manufacturer’s 
view point. Most of these products have health or structure/function claims on 
their packages with different actions like antihypertensive, blood-glucose lower-
ing, anxiolytic, and skin anti-aging activities. Although the different regional leg-
islations all aim to assure consumer safety and prevent misleading of the con-
sumer, the number of legally approved fish hydrolysate containing products dras-
tically differs among different regions. This is because products that have been positively evaluated 
based on safety and efficacy in one region were found to have not enough evidence for efficacy in 
another region. These findings call for further international harmonization of the regulation and clas-
sification of these products. Moreover, interaction studies of these bioactive products with the normal 
diet or medicines are generally not performed, keeping the consumer uninformed of the possible 
risks of combining these products with medicinal products or other food ingredients. 
Keywords: Bioactive marine peptides, fish hydrolysates, legal classification, regulatory affairs. 
INTRODUCTION 
 Today, much interest is given to the use of fish waste as a 
source of bioactive compounds. In 2014, the world capture 
fisheries and aquaculture production was 167.2 million tons 
and keeps increasing every year [1]. However, a significant 
part of the biomass, ranging from 30-60%, depending on the 
type of seafood and processing method, is not used for con-
sumption. These parts, including carcasses, heads, intestinal 
organs, fins and skin, are used as animal feed or crop fertil-
izer, or are discarded without processing [2, 3]. As the 
worldwide fishery resources are declining due to overfishing, 
there is a general trend in fish waste recuperation and proc-
essing as nutritional source but also as a source of bioactive 
molecules. 
 Different companies are focusing on the production of 
fish hydrolysates by processing protein rich fish materials 
with acids, bases, heath, or more often with exogenously 
added or endogenously produced enzymes. Depending on 
the used fish material, enzyme, and the reaction conditions, a 
variety of different peptides are produced which can be puri-
fied, for example, by membrane filtration or chromatography  
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[2]. A general flow for the production of fish hydrolysates by 
enzymatic hydrolysis is as follows: after mincing the protein 
rich fish waste with water and homogenizing it, enzymes are 
added and the digestion is started. When the desired grade of 
cleavage is obtained, the enzymes are inactivated by altering 
temperature or pH. The oil-water mixture is then centrifuged 
and/or filtered to remove the oil phase and/or insoluble parti-
cles and consequentially, the water fraction is removed by 
drying (e.g., lyophilization) resulting in the dry fish hydro-
lysate powder [4]. 
 Today, several of these peptide mixtures isolated from 
fish hydrolysates are marketed worldwide or studied for their 
favorable actions in several health domains like cardiovascu-
lar, dermatological, neurological, and metabolic areas. The 
search for fish-derived food products with activity in these 
domains receives much attention because of the high inci-
dence of lifestyle and aging-related diseases in the Western 
society. Therefore, this review gives an overview of the fish 
hydrolysates currently available for the consumer, including 
their claimed beneficial effects on health. Furthermore, the 
existing regulations and classifications regarding these food-
derived products with nutritional, physiological, and phar-
macological activities are evaluated and suggestions for im-
provement in their legal-regulatory classification are made. 
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THE USE OF HEALTH CLAIMS ON FOOD PROD-
UCTS THROUGH THE WORLD 
 Function foods, including food supplements, with health 
claims concerning cardiovascular, neurological or metabolic 
activities are available for the consumer. Examples include 
fish oil rich in omega-3 fatty acids, fermented red rice, garlic 
containing products, polyphenols from green tea and coen-
zyme Q10 [5]. Since the implementation of Regulation (EC) 
No. 1924/2006, the use of health claims on food products in 
Europe is better regulated and more harmonized [6]. The 
Scientific Panel on Dietetic Products, Nutrition and Allergies 
(NDA) of the European Food Safety Authority (EFSA) has 
provided guidelines to manufacturers and suppliers of food 
supplements and functional foods for placing health claims 
on their products. These guidelines include that the provided 
claims need to be well substantiated and a cause-effect rela-
tionship demonstrated (i.e., ‘generally accepted scientific 
evidence’) [6, 7]. Although the evaluation of these health 
claims is beneficial for the consumers’ safety, the stringency 
has resulted in a very low success rate of accepted claims. 
Especially the demand for generally accepted scientific evi-
dence is not easy to fulfil. Taking the different scientific 
opinions on the substantiation of health claims of food prod-
ucts reported in the EFSA journal into consideration, the 
weakness of some studies (such as not double-blinded, ani-
mal and in vitro studies, ...) can be identified as the main 
reason of failure. A well-founded clinical trial design is thus 
of the utmost importance. 
 Regulations about health claims on food are also avail-
able in Japan and the United States of America (USA). The 
Japanese Ministry of Health, Labor and Welfare (MHLW) 
introduced the Foods for Specified Health Uses (FoSHU) 
system, which is an approval system for the regulation of all 
health claims on packages of food products launched in Ja-
pan [8]. This status is granted to food that contains ingredi-
ents with a proven beneficial effect on health and a demon-
strated safety. FoSHU-approved products can put physio-
logical claims on their packages which must be priory ap-
proved by MHLW [8]. Furthermore, these products can also 
put the FoSHU label on their package, which can influence 
the consumers’ purchasing behavior and is therefore an im-
portant marketing factor. The use of these labels is unique 
compared to other regions and countries in the world [8, 9].  
 The US Government proclaimed the Nutritional Labeling 
and Education Act (NLEA) to regulate health claims and 
food labeling. Such health claims describe a relation between 
food, a food component, or a dietary supplement ingredient 
and the reduced risk of a disease or health-related condition 
[10]. The authorization of a claim is generally triggered by 
the submission of a health claim petition and the evaluation 
is performed based on an extensive scientific literature re-
view [8, 10, 11]. Next to the health claims, which are to be 
pre-approved by the food and drug administration (FDA), 
structure/function claims can also be placed on the packages 
of food or dietary supplements in the USA. The struc-
ture/function claims are regulated under the Dietary Supple-
ment Health and Education Act of 1994. They define the 
effect of a dietary supplement on the structure or function of 
the body e.g., ‘helps promote bone health’. These claims do 
not need to be pre-approved by the FDA and must be ac-
companied by the following disclaimer: ‘‘This statement has 
not been evaluated by the FDA. This product is not intended 
to diagnose, treat, cure or prevent any disease’’[10, 11]. The 
main difference between health and structure/function claims 
can be illustrated using the food ingredient fiber: “Three 
grams of soluble fiber from oatmeal daily in a diet low in 
saturated fat and cholesterol may reduce the risk of heart 
disease. This cereal has 2 grams per serving.” is accepted by 
the FDA as health claim: there is a clear effect relationship 
between the use of this food ingredient and the prevention of 
the heart disease. Compared to the claim "fiber maintains 
bowel regularity", which is a structure/function claim de-
scribing the relationship between the intake of a food ingre-
dient and the structure or function of the human body [10, 
12]. Most of the dietary supplements containing fish hydro-
lysates in the USA, e.g., Stabilium 200, Vasotensin, Pep-
tACE (all trademarks), have claims that fall in the struc-
ture/function class. 
MARKETED FISH HYDROLYSATES 
 The market of food supplements and functional foods is 
growing significantly in recent years. In a study of Leather-
head Food Research, the global functional food market is 
forecasted to grow to € 43 billion (US$ 47 billion) in 2017, 
which represents a 25% increase compared to 2013 [13]. The 
same growth is seen for dietary supplements, which had an 
estimated market of US$ 32 billion only in the USA in 2012 
[14]. This growth is related to the consumer’s awareness of 
the role of food in the prevention and development of dis-
eases like obesity, diabetes, cardiovascular diseases, osteopo-
rosis, intestinal cancer, etc. Today, Japan remains the most 
important player with 40% of the total global food market. In 
2013, 1095 FoSHU brands were marketed with a market size 
of ¥ 6275 billion (US$ 63 billion). Products with claims re-
lated to ‘intestinal and lactic acid bacteria’ were the most 
important (60.5%) followed by products with claims con-
cerning ‘neutral fat and body fat’ (22.4%) [8].  
 Although today, Japan remains the leading market, the 
high occurrence of obesity in the USA will be one of the 
main incentives for a shift from the East to the West. Fur-
thermore, the immense healthcare costs, related to these dis-
eases have also motivated the governments in their promo-
tion of the use of functional foods [15].  
 Currently, fish hydrolysates, in contrast to hydrolysates 
of milk and soy proteins, correspond to a small share of the 
food supplement and functional food consumption [16]. Al-
though already popular in Japan, also in Europe and the 
USA, more and more fish hydrolysate containing products 
are becoming available for the consumers under different 
trade names. A typical example is the antihypertensive prod-
uct Valtyron. Valtyron, a sardine muscle digest preparation 
with angiotensin converting enzyme (ACE) inhibiting prop-
erties, was first marketed in Japan by the company Senmi 
Ekisu Co. The product obtained the FoSHU status for blood 
pressure regulation. Valtyron is incorporated as supplement 
in health drinks, vegetable juices and beverages. In 2010, the 
EFSA-NDA panel decided that the product is safe to use as a 
novel food ingredient, i.e., defined as food that has not been 
consumed to a significant degree by humans in the EU prior 
to 1997 and regulated by Regulation (EU) 2015/2283, at a 
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level of 0.6 g/serving [17, 18]. Today, dietary supplements 
containing Valtyron are easily available through the internet 
all over the world. In 2011, Valtyron meeting food-grade 
specifications and manufactured according to cGMP was 
self-affirmed as generally recognized as safe (GRAS) 
(USA). It is used as an ingredient in a variety of food prod-
ucts at levels up to 30% or 0.6 g per serving [19]. Next to 
sardine peptide hydrolysates, also hydrolysates of other fish, 
like the bonito fish, are known for their antihypertensive 
effects and are available as dietary supplements on the Japa-
nese (Peptide ACE 3000), American (Vasotensin and Pep-
tACE) and Canadian (Levenorm) market [20]. 
 The health claims on marketed fish hydrolysates are not 
limited to antihypertensive activities. As can be seen in Ta-
ble 1, there are also products available, which may alter high 
blood glucose, stress, skin youth conditions, etc. 
 The products listed in Table 1 can be classified according 
to the claimed physiological activities. Stabilium 200, Seren-
lider, and Procalm claim to possess anxiolytic properties and 
are considered as beneficial for mental health and stress con-
ditions. The active ingredient in Serenlider is Protizen, which 
is a pollock and coalfish digest produced by enzymatic hy-
drolysis. No information regarding its composition nor any 
clinical trials have been published, though the manufacturer 
describes the product as ‘mood food’ as it is proclaimed to 
be used in stress relief and provides a natural feeling of well-
being while not lowering the attention [27]. Molval, a dietary 
supplement with claimed beneficial effects on dyslipidemia 
and cardiovascular risk evolution, contains next to omega-3 
fatty acids, the protein hydrolysate Gabolysat PC60. This 
fish peptide mixture also claims anxiolytic properties. In rats, 
the product has demonstrated stress responsiveness by influ-
encing the pituitary adrenal axis, the sympathoadrenal activ-
ity, and the γ-aminobutyric acid (GABA) content in hippo-
campus and hypothalamus in a similar way as the anxiolytic 
drug diazepam [36]. Another marketed fish hydrolysate con-
taining product with anxiolytic properties is Stabilium 200, 
which contains Garum armoricum and is available in the 
USA. According to the supplier, the product may be useful 
for reducing fatigue and supporting normal psychological 
functions, such as memory, concentration, and cognitive 
abilities [37]. Furthermore, Messaoudi et al. found anxiolytic 
and antidepressant-like effects of Garum armoricum in rats. 
[38]. Like most food supplements, the functional/structural 
claims and statements of Stabilium have not been evaluated 
by the FDA. 
 Several products containing fish hydrolysates have also 
reported metabolic activities. Slimpro contains the enzymatic 
hydrolysate of the northern blue whiting fish (Micromesis-
tius poutassou) and has been studied for its beneficial activ-
ity on body weight. In a randomized placebo-controlled and 
two-dose treatment study on 120 slightly overweighed sub-
jects (body mass index (BMI) between 25 and 30 kg/m²), the 
product was found to improve the body weight composition 
and to increase the blood concentration of cholecystokinin 
(CCK) and glucagon-like peptide-1 (GLP-1) [39]. These two 
anorexigenic signal molecules are produced by the duodenal 
I-cells and the intestinal L-cells, respectively, as a response 
to nutrient ingestion and are thus partly regulating energy 
homeostasis. Also the cod fish hydrolysate Nutripeptin is 
studied for its effect on weight management. However, in a 
randomized, double-blinded crossover study (n = 7; BMI > 
30 kg/m²), no beneficial effect of Nutripeptin (3 g of hydro-
lysate) was found for the measured metabolic parameter ab-
solute fat oxidation rate [40].  
 Two other important classes are fish collagen hydro-
lysates, used for their beneficial effect on skin health and 
photo-aging (e.g. Collactive and hydro MN peptide), and the 
ACE inhibitory, antihypertensive fish hydrolysates (e.g., 
Vasotensin, PeptACE, Valtyron, Protensin, Tensideal and 
Katsuobushi), which are discussed more in detail and in rela-
tion to their effect and regulatory framework in section 5 of 
this publication. 
SAFETY ASPECTS OF FISH HYDROLYSATE CON-
TAINING DIETARY SUPPLEMENTS AND FUNC-
TIONAL FOODS 
 As already mentioned, in Europe an application needs to 
be submitted and evaluated by the EFSA-NDA panel accord-
ing to Regulation (EC) No. 1924/2006, before any health 
claim can be used in combination with a dietary supplement 
or functional food, Although this panel will advise the Euro-
pean Commission about scientific substantiation of the 
health claim, it does not constitute an evaluation of the 
authorization for marketing the product, a decision on proper 
classification of the product as foodstuff nor a positive as-
sessment of its safety in its scientific opinion, whichis not 
foreseen in the framework of Regulation (EC) No. 
1924/2006. The decision whether a food ingredient is con-
sidered as safe is made after the European Commission re-
quests the EFSA-NDA panel a scientific opinion on the 
safety of the food ingredient (e.g., in the context of Regula-
tion (EC) No. 258/97). In its evaluation of the safety of the 
sardine peptide product Valtyron, the panel concluded that 
there is sufficient evidence to consider the product to be safe 
as food ingredient based on the absence of side effects in the 
different studies and the fact that the peptide product will be 
hydrolyzed in the small intestine into single amino acid con-
stituents prior to systemic absorption [17]. However, the 
arguments used for safety evaluation are in contrast with the 
FoSHU status granted to this product in Japan. This status 
was granted based on its safety and on its effect: if no toxic-
ity is expected because of the absence of intact peptides for 
systemic adsorption, no activity is expected as well. Differ-
ences in evaluation between Europe and Japan are also seen 
for other fish hydrolysates, such as antihypertensive bonito 
peptides. Bonito is a fish that has been traditionally con-
sumed in Japan and other Asian countries [41]. Its thermo-
lysin digest has antihypertensive activities in animals and on 
tissues, with the pentapeptide LKPNM being the main active 
component [41-43]. This hydrolysate gained the FoSHU 
status in 1997 [42]. However, during its evaluation of the 
scientific substantiation of the bonito peptide related health 
claim ‘maintenance of normal blood pressure’, the EFSA-
NDA panel decided that no cause-effect relationship was 
demonstrated between the consumption of bonito peptide 
(LKPNM) and maintenance of normal blood pressure [43]. 
 In the safety evaluation of food ingredients with claimed 
bioactivities, the interaction with other products, most impor-
tantly medicines, should be considered as well. The
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Table 1. Market products containing fish hydrolysates. 
Product name/ 
trade name 
Company (region) Source Production 
method 
Use according to supplier Form (according 
to supplier) 
Reference 
Seacure Proper nutrition Inc. 
(USA) 
Pacific whiting 
(cod) muscles 
Fermentation by 
microorganisms 
(yeast) 
Intestinal health Dietary supple-
ment 
[21] 
Collactive CTPP-Copalis (pro-
duction, France) 
PLT Health Solutions, 
Inc (USA).  
Wild caught fish 
skins 
Not available Hydration, 
anti-ageing, 
anti-oxidant 
Supplement, bev-
erage and func-
tional food prod-
ucts 
Nutricosmeceutical 
[22] 
Hydro MN 
peptide (part of 
Celergen) 
Celergen (Switzer-
land) 
Not available Not available Prevention of photo-aging, 
reduces the dietary glycemic 
index 
Nutritional sup-
plement 
[23] 
Slimpro Compagnie des pêches 
Saint-Malo Santé 
(France) 
Nutraceuticals Interna-
tional Group (USA) 
Northern blue 
whiting fish (Mi-
cromesistius pou-
tassou) 
Enzymatic 
hydrolysis 
Hunger control by increased 
production of CCK and GLP-
1 
Authorized for 
applications in 
food and dietary 
supplements 
[24] 
Nivelglu (con-
tains Nu-
tripeptin) 
Tongil (Spain) 
Nutrimarine Life 
Science AS, (Norway) 
(supplier nutripeptin) 
Cod Enzymatic 
hydrolysis 
Help to promote healthy 
blood sugar levels, can lower 
postprandial blood sugar to 
normal levels, helps to regu-
late sugar peaks after a meal, 
helps to improve blood glu-
cose control, helps to reduce 
plasma glucose levels, helps 
to limit the postprandial glu-
cose rise 
Dietary supple-
ment 
[25] 
Fortidium li-
quamen  
Biothalassol (France) White fish (Molva 
molva) 
Autolysate Reducing oxidative stress, 
lowering glycemic index, 
anti-stress 
Dietary supple-
ment 
[26] 
Procalm Copalis (France) White fish Not available Improve dog well-being  Veterinary (Ca-
nine) supplement 
[27] 
Stabilium 200 
(contains Ga-
rum armoni-
cum) 
Yalacta (France) Blue ling viscera 
(Molva dypterygia) 
Enzymatic 
autolysis 
Supports the body’s response 
to stress, provides nutritional 
support for memory and 
cognitive function 
Dietary supple-
ment 
[28] 
Serenlider 
(contains Proti-
zen) 
Naturlider (Spain) 
Copalis (France) 
Pollock 
Coalfish 
Enzymatic 
hydrolysis 
‘Mood food’ 
Stress relief action, provides a 
natural feeling of well-being 
while not lowering the atten-
tion 
Dietary supple-
ment 
[29] 
Molval (con-
tains Ga-
bolysat) 
Dielen (France) Blue ling (Molva 
dypterygia)  
Not available Cardiovascular protection and 
proper functioning of the 
heart, blood pressure and 
cholesterol balance, stress 
support 
Nutritional sup-
plement 
[30] 
Valtyron (main 
active peptide 
VY) 
Senmi Ekisu Co. 
(Japan) 
Sardine (Sardinops 
sagax) 
Alkaline prote-
ase hydrolysis 
Helps to maintain a healthy 
cardiovascular system 
Dietary supple-
ment and func-
tional food ingre-
dient 
[19] 
(Table 1) Contd…. 
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Product name/ 
trade name 
Company (region) Source Production 
method 
Use according to supplier Form (according 
to supplier) 
Reference 
Vasotensin 
(main active 
ingredient 
LKPNM) 
Metagenics (USA) Bonito fish (Sarda 
orientalis) 
Thermolysin 
digest 
Support healthy blood pres-
sure levels 
Dietary supple-
ment 
[31] 
PeptACE 
(main active 
ingredient 
LKPNM) 
Natural factors (USA) Bonito fish (Sarda 
orientalis) 
Thermolysin 
digest 
Natural support to lower high 
blood pressure, increases 
blood and oxygen flow to the 
heart, may improve heart 
function 
Dietary supple-
ment 
[32] 
Protensin Copalis (France) Not available Not available Inhibition properties of ACE Dietary supple-
ment 
[27] 
Tensideal  
 
ABYSS' ingredients 
(France) 
Mackerel Enzymatic 
hydrolysis 
Inhibition properties of ACE Dietary supple-
ment 
[33] 
Katsuobushi  Nippon supplements 
(Japan) 
Bonito fish (Sarda 
orientalis) 
Not available Support healthy blood pres-
sure levels already within the 
normal range 
Dietary supple-
ment and func-
tional food 
[34] 
Amizate Zymtech (Norway) Salmon (Salmo 
salar) 
Autolysate Amino acid source in diverse 
areas as malnutrition, wound 
treatment,  skin care, sports 
nutrition, wasting diseases, 
severe trauma following 
surgery 
Dietary supple-
ment  
[35] 
 
 antihypertensive fish hydrolysate peptides work by inhibit-
ing the ACE enzyme, which decreases blood pressure. These 
fish hydrolysates share their mode of action with some well-
known antihypertensive drugs like captopril, enalapril, and 
lysinopril, all structurally derived from peptides (Figure 1). 
Because of their common target, the interaction of antihyper-
tensive fish hydrolysates with these drugs must be evaluated 
as well. Long term combination of enalapril and the bonito 
peptide hydrolysate (LKPNM) resulted in a significantly 
reduced efficacy compared to enalapril monotherapy in male 
spontaneously hypertensive rats. The effect of the two sub-
stances was thus not synergic but rather opposite (competi-
tive): the hydrolysate partially adversed the effect of enala-
pril, possibly by interacting competitively with the catalytic 
site of ACE [44] (Figure 1). Similar results were obtained 
when co-administering dipeptide VY, the main active ingre-
dient of Valtyron, and the ACE-inhibitor captopril in sponta-
neously hypertensive rats. Although single oral administra-
tion of captopril (2.5 mg/kg) or VY (25 mg/kg) alone re-
sulted in a decrease of systolic blood pressure of 23 and 20 
mm Hg, respectively, but no significant effect on blood pres-
sure was seen when both products were combined [45]. The 
competition for peptide transport 1 (PEPT1), resulting in a 
decreased systemic adsorption from the gastro-intestinal 
tract, is found to lie on the basis of the loss in hypotensive 
effect (Figure 2).  
 Several fish hydrolysates are available with claimed anx-
iolytic activities and effectiveness on stress, e.g., Gabolysat 
PC60 having a similar effect as the drug diazepam in rats  
 
[36, 38]. Unfortunately, the effect of Gabolysat PC60 was 
only compared with diazepam, whereas the effect of co-
administration was not studied. However, it is likely that an 
interaction between anxiolytic fish hydrolysates and benzo-
diazepines, or other psychoactive medicines, may occur as 
interactions are demonstrated between most of the psychoac-
tive medicines as well as with some food ingredients like 
alcohol.  
 Another important functional group of fish-derived pro-
tein hydrolysates  influence blood sugar and may have a role 
in the regulation of blood glucose homeostasis, such as Nu-
tripeptin and Fortidium liquamen. Although no interaction 
studies of fish-derived peptides and DPP-IV inhibitors like 
stigaliptin have been reported, such studies are available 
between whey-hydrolysate peptides and stigaliptin, demon-
strating that a combination of these two products possess an 
additive DPP-IV inhibition, which may result in unwanted 
side reactions [46]. 
REGULATORY ASPECTS OF FISH HYDRO-
LYSATES 
 User’s safety is one of the major reasons, next to the fair 
competition and free movement of goods, for the European 
Union to create several regulations defining product classes 
of bioactive compounds. This classification is based on the 
product’s effect, presentation, use and origin, which offers 
manufacturers of bioactive products new and interesting op-
portunities for regulatory classification. Although each 
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Figure 2. Captopril and Valtyron (peptide VY) are absorbed from 
the gastro-intestinal tract and reach the systemic circulation by the 
PEPT1 transporter, co-transporting protons. However, when both 
products are administered simultaneously, they both influence each 
other’s absorption. 
 
product class has a clear definition with authored, but also 
obligated aspects, the creation of defined classes automati-
cally results in the creation of borderlines or grey zones, con-
taining products located between - and overlapping different 
product categories. Classification of products, including bor-
derline products, is carried out by the manufacturer, based on 
the intended use of the product and verified by the local 
authorities of the country where the manufacturer intends to 
market the product [47]. This is done case-by-case and there-
fore, especially for very innovative, complex products and 
because of the different perceptions of these regulations by 
the national authorities, identical cases may be differently 
classified. These differences increase the complexity of this 
matter and the regulatory uncertainty for manufacturers. Two 
examples are the C-109/12 case, concerning the classifica-
tion of Gynocaps, i.e. lactobacillus containing vaginal cap-
sules, as a medicinal product in one country and as medical 
device in other countries and the C-140/07 case, concerning 
the classification of Red Rice 330 mg capsules as medicinal 
product in one country and as food supplement in other 
countries [48, 49]. Proper classification by the national 
authorities should be done based on all aspects of the product 
and not only on the ingredients’ identity without taking into 
consideration the classification of similar, already approved 
products.  
 Especially the border between medicinal products and 
food supplements is a matter of frequent debates. Both prod-
ucts are dosed in the same pharmaceutical form (capsules, 
tablets, and oral liquids) and contain bioactive substances. 
Although the presentational and functional aspects of me-
dicinal products, 
“i.e. presented as having properties for treating or prevent-
ing disease in human beings or may be used in or adminis-
tered to human beings either with a view to restoring, cor-
recting or modifying physiological functions by exerting a 
pharmacological, immunological or metabolic action, or to 
making a medical diagnosis” [50] 
are different than that of food supplements, 
“i.e. foodstuffs the purpose of which is to supplement the 
normal diet and which are concentrated sources of nutrients 
or other substances with a nutritional or physiological ef-
fect” [51] 
 
Figure 1. Captopril, Valtyron (VY) and the bonito hydrolysate peptide (LRPNM) are all inhibitors of ACE, which convert angiotensin I in 
hypertensive angiotensin II. The simultaneous administration of an ACE-inhibitor (captopril or enalpril) with one of these fish hydrolysates 
results in activity loss of both components. 
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it is demonstrated that borderline cases are unpreventable 
due to different interpretation of some aspects in the defini-
tions (e.g., physiological effect), similar ingredients (e.g., 
botanicals), and the same presentation forms [47-49, 52]. In 
general, a medicine is linked to a disease (which is expected 
to be handled by the medicine), while a food product is asso-
ciated with a healthy person (who wants to maintain or im-
prove his healthy state), broadening this legal-regulatory 
product classification discussion also towards the “disease” 
semantics, e.g., from which blood pressure or cholesterol 
blood-level becomes a healthy person a diseased one. A de-
cision needs to be made based on the definition of the prod-
uct classes, the available studies and evidence, and similar or 
relevant precedents at the European Court of Justice (ECJ) or 
domestic courts. Indeed, in those cases with undisputable 
doubt, the ECJ can be requested to provide judgement. How-
ever, whenever the product falls within both the definition of 
a medicinal product and at least another product class, the 
strictest directive, i.e., concerning medicinal products, shall 
apply [50]. The proper classification of a product can also 
have important implications for the manufacturer. Especially 
the gap between the requirements for the regulation of a me-
dicinal product and a food product is vast. 
 Some fish hydrolysates are also located at the borderline 
between foods and cosmetics. The European Union Cosmet-
ics Directive defines a cosmetic as "any substance or prepa-
ration intended to be placed in contact with the various ex-
ternal parts of the human body or with the teeth and the mu-
cous membranes of the oral cavity with a view exclusively or 
mainly to cleaning them, perfuming them, changing their 
appearance and/or correcting body odors and/or protecting 
them or keeping them in good condition" [53]. The so called 
‘nutricosmeceuticals’ contain food ingredients that have a 
beneficial effect on the external parts of our body by chang-
ing their appearance. Although they contain food ingredients 
and are presented in capsules, the fact that they have an es-
thetical action on the skin makes them lean close to the defi-
nition of cosmetics. Examples are fish hydrolysates Collac-
tive™ and Hydro MN, which goth contain hydrolyzed colla-
gen and elastin protein from fish and are claimed to have an 
anti-wrinkle action [54]. Hydrolyzed collagen is digested 
into small peptides and amino acids, which are absorbed and 
distributed in the human body. When reaching the dermis, 
the amino acids function as building blocks in the collagen 
synthesis, whereas the oligopeptides can interact with recep-
tors on fibroblasts and stimulate the production of new colla-
gen, elastin, and hyaluronic acid [55].  
 Although regional differences exist for the acceptance of 
health claims on fish hydrolysates (e.g., bonito peptides, 
Valtyron), the question remains if some of these hydrolysates 
are safe to be used by the consumer as dietary supplement or 
functional food in an uncontrolled way. The ACE inhibitor 
fish peptides for example, which interact with the ACE en-
zyme, share their target with some prescription medicines 
(e.g. captopril, enalapril, and lysinopril). ACE inhibitory fish 
peptides can thus be considered as borderline cases of prod-
ucts that are situated between medicinal products and food 
(dietary supplements and functional food). The classification 
of these hypotensive products resembles to the Hecht-
Pharma case regarding the proper classification of yeast fer-
mented red rice capsules containing 1.33 mg monacolin k, 
which is synonymous with lovastatin, an inhibitor of the cho-
lesterol synthesis and active substance in several prescription 
medicinal products [49]. According to the supplier, the prod-
uct can be categorized as dietary supplement, because the 
dose of monacolin k (1-3 capsules a day = 1.33- 4 mg) is too 
low for exerting a pharmacological effect (compared to 10 – 
80 mg as recommended daily dose of lovastatin). The ECJ 
agreed that the fermented red rice capsules are classified as 
dietary supplement and stated that “products containing a 
substance having a physiological effect cannot automatically 
be classified as medicinal products by function. Apart from 
the case of substances or combinations of substances in-
tended for the purpose of making a medical diagnosis, a 
product cannot be regarded as being a medicinal product by 
function where, having regard to its composition – including 
its content in active substances – and if used as intended, it 
is incapable of appreciably restoring, correcting or modify-
ing physiological functions in human beings.” 
 Some similarities can be found between the Hecht-
Pharma case and the hypotensive sardine and bonito hydro-
lysates: both products originate from processed food with an 
active ingredient that is structurally related to marketed pre-
scribed medicinal products (statins and ACE-inhibitors) and 
historically used for their beneficial effects on health in 
many regions worldwide. However, fish hydrolyzed products 
tested in clinical studies showed significant hypotensive ef-
fects for doses that are the same as those proposed by the 
suppliers of these products as daily intake [43, 56, 57]. A 
pharmacological action is thus demonstrated. Furthermore, 
the available case reports of patients encountering (serious) 
side-effects after using these ‘pharmacological inactive’ die-
tary supplements, e.g., fermented red rice, demonstrate that 
the classification of physiological active products should be 
done with care [58]. 
CONCLUSION 
 For the first time introduced on the Japanese market more 
than 25 years ago, bioactive fish hydrolysates are now avail-
able all over the world as food supplements, functional food 
ingredients, and ‘nutricosmeceuticals’. Different actions like 
antihypertensive, blood-glucose lowering, anxiolytic, and 
skin anti-aging activities have been demonstrated in animals 
and humans, but most scientific evidence has not been rigor-
ously controlled by competent authorities making them pos-
sibly misleading to the consumer. Using the current regula-
tory classification systems and regulations, inconsistency in 
the interpretation and application of these regulations as well 
as in the requirements for authorization exists. This results in 
international differences in the number and use of available 
fish hydrolysates containing products. Interaction studies 
with normal diet and/or medicines are available only for a 
limited number of products and they demonstrate that the use 
of these bioactive fish hydrolysates is not without risk. Cur-
rently, these studies are not required and as a result, even for 
most authorized products, consumer safety is not guaranteed. 
FUTURE CONSIDERATIONS AND/OR RECOM-
MENDATIONS 
 In contrast to the international harmonization of pharma-
ceuticals for human use (e.g., International Conference on 
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Harmonisation (ICH) guidelines and the international phar-
maceutical regulators forum (IPRF)), the harmonization for 
food with physiological functions (functional food, food 
supplements) is lagging behind. The existing differences 
among the USA, EU, and Japan in the evaluation of products 
with health- and/or functional claims have led to unbalanced 
numbers of available products in different regions and coun-
tries. To ensure the availability of these products to the con-
sumer, having possible beneficial health effects, and to pro-
mote international trade eliminating discrimination, while 
still maintaining an acceptable level of safety and informa-
tion, a uniform science based assessment should be the basis 
for the evaluation of the safety and functionality of fish hy-
drolysates and derived products. Furthermore, as is obligated 
for medicinal products, the market responsible for these fish 
hydrolysates must inform the consumer about the possible 
risk when combining these biologically active substances 
with medicinal products and/or other food ingredients. 
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